These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Ensing K; de Zeeuw RA; Nossent GD; Koëter GH; Cornelissen PJ Eur J Clin Pharmacol; 1989; 36(2):189-94. PubMed ID: 2524387 [TBL] [Abstract][Full Text] [Related]
25. Bioavailability of dihydroergotamine in man. Little PJ; Jennings GL; Skews H; Bobik A Br J Clin Pharmacol; 1982 Jun; 13(6):785-90. PubMed ID: 7093108 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of metformin after intravenous and oral administration to man. Pentikäinen PJ; Neuvonen PJ; Penttilä A Eur J Clin Pharmacol; 1979 Sep; 16(3):195-202. PubMed ID: 499320 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers. Norbury HM; Franklin RA; Graham DF Eur J Clin Pharmacol; 1983; 25(1):77-80. PubMed ID: 6617729 [TBL] [Abstract][Full Text] [Related]
28. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Hedner T; Persson B; Berglund G Br J Clin Pharmacol; 1983 Aug; 16(2):121-5. PubMed ID: 6615685 [TBL] [Abstract][Full Text] [Related]
29. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects. Gasic S; Eichler HG; Korn A J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071 [TBL] [Abstract][Full Text] [Related]
30. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. Hedner T; Persson B Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724 [TBL] [Abstract][Full Text] [Related]
31. Ranitidine bioavailability and kinetics in normal male subjects. Garg DC; Weidler DJ; Eshelman FN Clin Pharmacol Ther; 1983 Apr; 33(4):445-52. PubMed ID: 6299642 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure. Sorensen EV; Faergeman O; Day M; Bastain W Eur J Clin Pharmacol; 1988; 35(2):183-5. PubMed ID: 2903827 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery. Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078 [TBL] [Abstract][Full Text] [Related]
34. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212 [TBL] [Abstract][Full Text] [Related]